These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8906289)

  • 1. Persistent microvasculopathy in chronic eosinophilia-myalgia syndrome.
    Smith SA
    Adv Exp Med Biol; 1996; 398():359-64. PubMed ID: 8906289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L-tryptophan syndrome: histologic features of scleroderma-like skin changes.
    Guerin SB; Schmidt JJ; Kulik JE; Golitz LE
    J Cutan Pathol; 1992 Jun; 19(3):207-11. PubMed ID: 1401345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the pathology of fascia in eosinophilic myalgia syndrome patients and idiopathic eosinophilic fasciitis.
    Umbert I; Winkelmann RK; Wegener L
    Dermatology; 1993; 186(1):18-22. PubMed ID: 8435512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-tryptophan and the eosinophilia-myalgia syndrome: current understanding of the etiology and pathogenesis.
    Varga J; Jimenez SA; Uitto J
    J Invest Dermatol; 1993 Jan; 100(1):97S-105S. PubMed ID: 8423409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [L-tryptophan-associated chronic eosinophilia-myalgia syndrome treated with cyclosporin].
    Schubert S; Trautmann F; Dreher R
    Z Rheumatol; 1992; 51(4):158-62. PubMed ID: 1414039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eosinophilia-myalgia syndrome among the non-L-tryptophan users and pre-epidemic cases.
    Sullivan EA; Staehling N; Philen RM
    J Rheumatol; 1996 Oct; 23(10):1784-7. PubMed ID: 8895159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microangiopathy in the eosinophilia-myalgia syndrome.
    Smith SA; Roelofs RI; Gertner E
    J Rheumatol; 1990 Nov; 17(11):1544-50. PubMed ID: 2273500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The natural history of eosinophilia-myalgia syndrome in a tryptophan-exposed cohort in South Carolina.
    Sullivan EA; Kamb ML; Jones JL; Meyer P; Philen RM; Falk H; Sinks T
    Arch Intern Med; 1996 May; 156(9):973-9. PubMed ID: 8624177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-tryptophan-induced eosinophilia-myalgia syndrome. I. Report of two cases with pseudoxanthoma-elasticum-like skin changes.
    Mainetti C; Schmied E; Masouyé I; Chavaz P; Saurat JH
    Dermatologica; 1991; 183(1):57-61. PubMed ID: 1769422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Eosinophilic fasciitis (Shulman syndrome). Differential diagnosis of chronic eosinophilia-myalgia syndrome after L-tryptophan administration].
    Schnabel A; Reusch M; Christophers E; Gross WL
    Internist (Berl); 1994 Jan; 35(1):63-6. PubMed ID: 8144322
    [No Abstract]   [Full Text] [Related]  

  • 11. Immune-mediated mechanisms and immune activation of fibroblasts in the pathogenesis of eosinophilia-myalgia syndrome induced by L-tryptophan.
    Illa I; Dinsmore S; Dalakas MC
    Hum Pathol; 1993 Jul; 24(7):702-9. PubMed ID: 8100551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bias or biology: evaluating the epidemiologic studies of L-tryptophan and the eosinophilia-myalgia syndrome.
    Horwitz RI; Daniels SR
    J Rheumatol Suppl; 1996 Oct; 46():60-72. PubMed ID: 8895182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiologic studies of the association of L-tryptophan with the eosinophilia-myalgia syndrome: a critique.
    Shapiro S
    J Rheumatol Suppl; 1996 Oct; 46():44-58; discussion 58-9. PubMed ID: 8895181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demyelinating polyneuropathy in eosinophilia-myalgia syndrome.
    Donofrio PD; Stanton C; Miller VS; Oestreich L; Lefkowitz DS; Walker FO; Ely EW
    Muscle Nerve; 1992 Jul; 15(7):796-805. PubMed ID: 1323757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tryptophan contaminants associated with eosinophilia-myalgia syndrome. The Eosinophilia-Myalgia Studies of Oregon, New York and New Mexico.
    Philen RM; Hill RH; Flanders WD; Caudill SP; Needham L; Sewell L; Sampson EJ; Falk H; Kilbourne EM
    Am J Epidemiol; 1993 Aug; 138(3):154-9. PubMed ID: 8356958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased type I collagen gene expression in L-tryptophan associated eosinophilia-myalgia syndrome skin fibroblasts.
    Varga J; Li L; Jimenez SA
    J Rheumatol; 1993 Aug; 20(8):1303-8. PubMed ID: 8230009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic fatigue: a peculiar evolution of eosinophilia myalgia syndrome following treatment with L-tryptophan in four Italian adolescents.
    Priori R; Conti F; Luan FL; Arpino C; Valesini G
    Eur J Pediatr; 1994 May; 153(5):344-6. PubMed ID: 8033924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of the eosinophilia-myalgia syndrome].
    Ishikawa A; Akahosi T; Okada J; Kondo H; Kasiwazaki S
    Ryumachi; 1992 Aug; 32(4):327-30; discussion 330-2. PubMed ID: 1411794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrogenic growth factors in the eosinophilia-myalgia syndrome and the toxic oil syndrome.
    Kaufman LD; Gruber BL; Gomez-Reino JJ; Miller F
    Arch Dermatol; 1994 Jan; 130(1):41-7. PubMed ID: 8285738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathologic manifestations of the eosinophilia myalgia syndrome: analysis of 11 cases.
    Lin JD; Phelps RG; Gordon ML; Hilfer JB; Wolfe DE; Venkataseshan VS; Fleischmajer R
    Hum Pathol; 1992 Apr; 23(4):429-37. PubMed ID: 1563745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.